Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Executive Summary
The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.